Abstract
There is a growing interest in developing microphysiological systems that can be used to model both normal and pathological human organs in vitro. This “organs-on-chips” approach aims to capture key structural and physiological characteristics of the target tissue. Here we describe in vitro vascularized microtumors (VMTs). This “tumor-on-a-chip” platform incorporates human tumor and stromal cells that grow in a 3D extracellular matrix and that depend for survival on nutrient delivery through living, perfused microvessels. Both colorectal and breast cancer cells grow vigorously in the platform and respond to standard-of-care therapies, showing reduced growth and/or regression. Vascular-targeting agents with different mechanisms of action can also be distinguished, and we find that drugs targeting only VEGFRs (Apatinib and Vandetanib) are not effective, whereas drugs that target VEGFRs, PDGFR and Tie2 (Linifanib and Cabozantinib) do regress the vasculature. Tumors in the VMT show strong metabolic heterogeneity when imaged using NADH Fluorescent Lifetime Imaging Microscopy and, compared to their surrounding stroma, many show a higher free/bound NADH ratio consistent with their known preference for aerobic glycolysis. The VMT platform provides a unique model for studying vascularized solid tumors in vitro.
Highlights
There is a growing interest in developing microphysiological systems that can be used to model both normal and pathological human organs in vitro
The growing use of tumor spheroids addresses some of these shortcomings – the cells are in a 3D environment and stromal cells may be present[7]
The vascularized micro-organ (VMO) platform allows for the reproducible creation of perfused vascular networks in vitro
Summary
There is a growing interest in developing microphysiological systems that can be used to model both normal and pathological human organs in vitro This “organs-on-chips” approach aims to capture key structural and physiological characteristics of the target tissue. We describe in vitro vascularized microtumors (VMTs) This “tumor-on-a-chip” platform incorporates human tumor and stromal cells that grow in a 3D extracellular matrix and that depend for survival on nutrient delivery through living, perfused microvessels. Proliferation rates may differ, metabolic profiles may be altered, and dose-response curves for some drugs can differ by orders of magnitude[5,6] This may result from targets not being expressed in 2D, from survival pathways being activated in 3D, or from contributions by stromal cells. We have incorporated tumor cells into the VMO www.nature.com/scientificreports/
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
